News und Analysen
NeutriSci Provides Update Regarding Product Launch in California
Vancouver, British Columbia – August 12, 2020 – NeutriSci International Inc. (“NeutriSci” or the “Company”) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9), an innovative technology company
NeutriSci: Neuigkeiten zur Produkteinführung in Kalifornien
Vancouver, British Columbia – 12. August 2020 – NeutriSci International Inc. („NeutriSci“ oder das „Unternehmen“) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) – ein innovatives
Aurinia Reports Second Quarter 2020 Financial Results and Recent Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (Aurinia or the Company) today reported financial results for the second quarter ended June 30, 2020 and provided an update on recent
THERANEXUS AND BBDF OBTAIN ORPHAN DRUG DESIGNATION (ODD) AND RARE PEDIATRIC DISEASE DESIGNATION (RPDD) FROM THE FOOD AND DRUG ADMINISTRATION (FDA) FOR BBDF-101 FOR BATTEN DISEASE
- Orphan Drug Designation (ODD) is a status that provides seven years of additional post-approval protection and exemption from filing fees
- Rare Pediatric Disease Designation (RPDD) qualifies the
Epigenomics: Aktie knallt nach Studiennews – so geht es weiter!
Neue medizinische Erkenntnisse sorgen für frischen Schwung im Handel mit Epigenomics-Aktien (WKN: A11QW5). Die Ergebnisse der im "Journal of the National Cancer Institute" (JNCI) erschienenen Studie
Pfenex mit +109% in 3 Monaten: Nächster Buyout für den NBC!
Mit Pfenex (WKN: A118RA) meldet die Mai-Empfehlung des No Brainer Clubs ein lukratives Übernahmeangebot. NBC-Mitglieder liegen damit in nur drei Monaten mindestens +109% vorne.
Anfang Mai empfahlen
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on August 4, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
Jubilant Radiopharma and Navidea Biopharmaceuticals Sign Binding Memorandum of Understanding for Commercialization Partnership
Jubilant Radiopharma, a business unit of Jubilant Pharma Limited and Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) announced today that both companies have signed a binding memorandum of
Sangamo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that Sandy Macrae, CEO of Sangamo, will present at the 2020 Wedbush PacGrow Healthcare Conference on August
Navidea Biopharmaceuticals Signs Binding Framework for Commercialization Partnership with Jubilant Radiopharma
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to
Pfizer Announces Agreement with Gilead to Manufacture Remdesivir for Treatment of COVID-19
Pfizer Inc. (NYSE: PFE) today announced a multi-year agreement with Gilead Sciences, Inc. to manufacture and supply Gilead’s investigational antiviral remdesivir, as one of multiple external
Medigene berichtet über 2. Quartal und veröffentlicht Halbjahresbericht 2020
Telefonkonferenz heute, 7. August 2020 um 14.00 Uhr MEZ (in englischer Sprache)
Unternehmensmitteilung für den Kapitalmarkt
Martinsried/München (07.08.2020) - Die Medigene AG (Medigene,
Medigene provides Q2 update and 6M report 2020
Conference call on 7 August 2020 at 2pm CET (Frankfurt) / 8am EDT (New York)
Business news for the stock market
Martinsried/ Munich (07.08.2020) - Medigene AG (Medigene, FSE: MDG1, Prime
Clovis Oncology Announces Second Quarter 2020 Operating Results
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended June 30, 2020, and provided an update on the Company’s clinical development programs and regulatory and
Savara Reports Second Quarter 2020 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the second quarter ending June 30, 2020 and provided a business update.
“With a final design for
Navidea Biopharmaceuticals to Host Second Quarter 2020 Earnings Conference Call and Corporate Update
Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced
Puma Biotechnology Reports Second Quarter 2020 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2020. Unless otherwise stated, all comparisons are for the
THERANEXUS : DECLARATION OF TOTAL NUMBER OF SHARES AND VOTING RIGHTS
Lyon, August 6, 2020 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction
Pfizer Announces Times for Rescheduled Virtual Investor Day on September 14 and September 15, 2020
Pfizer Inc. (NYSE: PFE) announced today that it will be holding its rescheduled Investor Day virtually over two days: Monday, September 14, 2020 from 1:00 p.m. EDT to approximately 4:00 p.m. EDT
MorphoSys: Anlegern gefällt der Ausblick nicht, aber...
Erst am vergangenen Wochenende konnte das deutsche Biotechunternehmen MorphoSys (WKN: 663200) einen großen Erfolg verbuchen, nämlich die FDA-Zulassung des Krebsmittels Monjuvi. Daraufhin machte die
Biofrontera: Die US-Zocker drehen jetzt völlig durch!
Aufgrund der Covid-19-Pandemie bedingten Wirtschaftskrise gibt es in den USA plötzlich ein Sozialsystem. Welch seltsame Blüten dies treibt, zeigt sich nun ausgerechnet beim deutschen
Antibe Therapeutics Engages Stern IR for Investor Relations Services
Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) today announces that it has engaged Stern Investor Relations, Inc. (“Stern IR”) to expand the Company’s investor relations program and support
Vifor Pharma Group Reports Continued Growth in H1 2020
Regulatory News:
Vifor Pharma Group reported growth in H1 2020, despite challenges to patient access conditions caused by the COVID-19 pandemic. The financial guidance has been updated to reflect
Vifor Pharma Gruppe wächst auch im 1. Halbjahr 2020 weiter
Regulatory News:
Die Vifor Pharma Gruppe ist trotz der Herausforderungen, die Patienten auch während der COVID-19-Pandemie zu erreichen, im 1. Halbjahr 2020 weiter gewachsen. Die Finanzprognose
FDA Approves GSK’s BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved BLENREP (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed